期刊文献+

生物制品中宿主残留蛋白的风险分析和检测方法 被引量:4

Risk analysis and detection strategy of residual host cell protein in biological products
原文传递
导出
摘要 新版《中华人民共和国药典》对生物制品的质量要求更高,其中对残留宿主细胞蛋白(HCP)在生物制品中含量的要求也越来越严格。目前HCP研究领域进展迅速。此文对生物制品中宿主残留蛋白的风险分析和检测方法作一综述。 Higher quality for the biological products is required in the latest edition of Pharmacopoeia of the People's Republic of China, and the control on the residual host cell protein (HCP) in biological products is more rigorous. Recently, the progress in the research of residual HCP is very rapid. This paper reviews risk analysis and detection strategy of residual HCP.
出处 《国际生物制品学杂志》 CAS 2012年第2期82-86,共5页 International Journal of Biologicals
关键词 生物制品 宿主细胞蛋白 风险分析 系统生物学 Biological products Host cell protein Risk analysis Systems biology
  • 相关文献

参考文献21

  • 1国家药典委员会.中华人民共和国药典2010年版三部[S]北京:中国医药科技出版社,2010.
  • 2Vincent-Falquet JC,Peyron L,Souvras M. Qualification of working cell banks for the Vero cell line to produce licensed human vaccines[J].Developments in Biological Standardization,1989.153-156.
  • 3Petricciani JC,Levenbook IS,Wierenga DE. Early passage primate cell immortality is independent of tumorigenicity[J].In Vitro Cellular & Developmental Biology,1987,(07):523-526.doi:10.1007/BF02628424.
  • 4Xue L,Johnson R,Gorovits B. Prevalence and isotypic complexity of the anti-Chinese hamster ovary host cell protein antibodies in normal human serum[J].AAPS JOURNAL,2010,(01):98-106.doi:10.1208/s12248-009-9165-5.
  • 5Zobrist JM,Cresswell JR,Valdes-Camin R. Detergent optimization for total protein extraction from Chinese hamster ovary (CHO)cells[J].Life Sci Innov,2006,(01):28-29.
  • 6Krawitz DC,Forrest W,Moreno GT. Proteomic studies support the use of multi-product immunoassays to monitor host cell protein impurities[J].Proteomics,2006,(01):94-110.doi:10.1002/pmic.200500225.
  • 7Wang X,Hunter AK,Mozier NM. Host cell proteins in biologics development:Identification,quantitation and risk assessment[J].Biotechnology and Bioengineering,2009,(03):446-458.doi:10.1002/bit.22304.
  • 8Anderson NL,Anderson NG. The human plasma proteome:History,character,and diagnostic prospects[J].Molecular and Cellular Proteomics,2002,(11):845-867.
  • 9Waterston RH,Lindblad-Toh K,Birney E. Initial sequencing and comparative analysis of the mouse genome[J].Nature,2002,(6915):520-562.
  • 10Nick C. Confronting the challenges in developing a biosimilar medicinal product[M].Haslemere:Euromed Communications Ltd,2006.

二级参考文献12

  • 1田博,靳萍,黄浩,丁志芬.Vero细胞蛋白过敏原性研究[J].中国生物制品学杂志,2004,17(6):372-373. 被引量:1
  • 2田博,丁志芬.酶标法相对定量检测Vero细胞疫苗中宿主细胞蛋白[J].中国生物制品学杂志,2005,18(2):159-161. 被引量:6
  • 3Vincent RA,Eileen FF,Baron RR,et al.Immunoassay for the detection of E.coli proteins in recombinant DNA derived human growth hormone[J].J Immunol Methods,1986,91:213-224.
  • 4O′keefe DO,DePhillips P,Will ML.Identification of an Escherichia coli protein impurity in preparations of a recombinant pharmaceutical[J].Pharmaceutical Research,1993,10(7):975-979.
  • 5Eaton LC.Host cellcontaminant protein assay development for recombinant biopharma ceuticals[J].J Chromatography A,1995,705:105-114.
  • 6Dagouassat N, Haeuw JF, Robillard V, et al. Development of a quantitative assay for residual host cell protein in arecombinant subunit vaccine against human respiratory syncytial virus[J].J Immunol Methods,2001,251:151-159.
  • 7Fryklund L,Brandt J, Hagerman M, et al. Methionyl human growth hormone (Somatonorm):purity and properties-human growth hormones[M].New York,1986.257-266.
  • 8中华人民共和国卫生部.中国生物制品规程[S].北京:化学工业出版社,2000.409-413.
  • 9WHO requirements for continuous cell lines used foe biological production (1987). Requirements for biological substances No 37. Technical Report Series No. 745.93-107, WHO, Geneva.
  • 10Requirement for the use of animal cells as in vitro substrates for the production of biologicals. Tech Rept Series. 1998.878:19-56.

共引文献23

同被引文献19

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部